NCT05247879已完成不适用
Clinical Effectiveness and Safety of a Novel Oral Rehydration Solution in Children Ages 1-5 Years Presenting to Hospital With Mild or Moderate Dehydration Gastroenteritis: Randomized, Open-label, Controlled Trial
Mead Johnson Nutrition4 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年6月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 4
- 主要终点
- Clinically assessed adequate rehydration based on clinical judgement of change in or absence of presenting symptoms from baseline (i.e. heart rate, urine output, etc.)
研究概览
简要总结
This is a randomised, controlled, open-label study to determine the clinical effectiveness and safety of a novel ORS compared with a commercial ORS in children 1 to 5 years of age attending emergency departments with gastroenteritis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 5 Years(Child)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1 to 5 years of age, inclusive at randomization
- •Hospitalized with mild to moderate dehydration due to ongoing diarrhea
- •Signed informed consent obtained for child's participation in the study
排除标准
- •Severe dehydration and/or use of IV fluids for current hospitalization
- •Experiencing bloody diarrhea or diarrhea due to Cholera, Dysentery, persistent/chronic diarrhea, diarrhea with severe malnutrition, diarrhea associated with recent antibiotic use
- •In the opinion of the Investigator, not suitable for treatment with ORS
- •Have any underlying disease or disorder that may, in the opinion of the Investigator, affect the results of the study if they were enrolled (includes, but is not limited to, gastrointestinal disorders such as Crohn's disease or other inflammatory bowel disease or congenital malabsorption disorders)
- •Cause of the dehydration is something other than diarrhea
- •Known to be allergic to any of the components of the Investigational ORS
结局指标
主要结局
Clinically assessed adequate rehydration based on clinical judgement of change in or absence of presenting symptoms from baseline (i.e. heart rate, urine output, etc.)
时间窗: every 4 hours up to 24 hours or hospital discharge, whichever occurs first
Assess change in clinical hydration status from presenting baseline status
次要结局
- Study ORS intake (units)(Every 4 hours up to 24 hours or hospital discharge, whichever occurs first)
- Use of IV fluids(up to 24 hours or hospital discharge, whichever occurs first)
- Parent satisfaction questionnaire(baseline and 24 hours or hospital discharge, whichever occurs first)
- Frequency of vomiting(every 4 hours up to 24 hours or hospital discharge, whichever occurs first)
- Record patient use of antibiotics during hospitalization(up to 24 hours or hospital discharge, whichever comes first)
- Participant comfort questionaire(baseline and 24 hours or hospital discharge, whichever occurs first)
- Frequency episodes of urination(every 4 hours up to 24 hours or hospital discharge, whichever occurs first)
- Time ready for discharge(At discharge or 48 hours whichever occurs first)
- Frequency of liquid/watery stool(every 4 hours up to 24 hours or hospital discharge, whichever occurs first)
- Medically confirmed adverse events collected throughout the study period(0 hours through 7 days post discharge)
- Weight(Every 4 hours up to 24 h or at hospital discharge, whichever occurs first)
- Time to resolution of liquid/water stool(up to 24 hours or hospital discharge, whichever comes first)
- Clinical Assessment of patient's hydration status based on presenting symptoms (i.e. heart rate, urine output, etc.)(Baseline)
- Stool for bacterial pathogen culture and viral antigens(up to 24 hours or hospital discharge, whichever comes first)
研究者
研究点 (4)
Loading locations...
相似试验
终止
不适用
A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With DermatomyositisDermatomyositisNCT01140503Stanford University5
已完成
2 期
Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19COVID-19NCT05164120MedStar Health43
已完成
2 期
A Long Term Safety Study of BCX7353 in Hereditary AngioedemaHAEProphylaxisHereditary AngioedemaNCT03472040BioCryst Pharmaceuticals387
已完成
1 期
Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects with Diabetic Macular EdemaDiabetic Macular EdemaNCT05699759Michelle Abou-Jaoude1
Unknown
3 期
Philippine Trial to Determine Efficacy and Safety of Favipiravir for COVID-19Covid19NCT05014373University of the Philippines144
